candesartan has been researched along with Precancerous Conditions in 1 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Precancerous Conditions: Pathological conditions that tend eventually to become malignant.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Candesartan treatment was associated with increased iNOS expression (p = ." | 2.84 | Support for involvement of the renin-angiotensin system in dysplastic Barrett's esophagus. ( Bratlie, SO; Casselbrant, A; Edebo, A; Fändriks, L, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bratlie, SO | 1 |
| Casselbrant, A | 1 |
| Edebo, A | 1 |
| Fändriks, L | 1 |
1 trial available for candesartan and Precancerous Conditions
| Article | Year |
|---|---|
Support for involvement of the renin-angiotensin system in dysplastic Barrett's esophagus.
Topics: Adenocarcinoma; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2017 |